Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
ENTITY
SMARTSCORE: 4.2/5
Shionogi & Co (4507 JP)
Watchlist
103
Analysis
Health Care
•
Japan
Shionogi & Company Ltd., is a pharmaceutical company. The Company develops prescription & over-the-counter drugs and diagnostics.
more
Watchlist
All
Insights
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
•
Kyowa Kirin Co Ltd
•
19 Feb 2024 01:30
Kyowa Kirin (4151 JP): Recent Portfolio Strengthening Initiatives to Accelerate Long-Term Growth
Kyowa Kirin partners with Bridgebio for infigratinib in Japan and enrolls first patient in Phase 2 trial for tivozanib eye drop for DME. Higher...
Tina Banerjee
Follow
316 Views
Share
bearish
•
Eisai Co Ltd
•
03 Jan 2024 01:30
Eisai Co Ltd (4523 JP): Why Performance Reversal Is Not Expected in Near-Term
Eisai shares are on downtrend due to disappointment with Alzheimer's drug. Top-selling drug Lenvima faces patent expiration in 2025. Eisai seeks...
Tina Banerjee
Follow
663 Views
Share
bullish
•
Thematic (Sector/Industry)
•
24 Dec 2023 01:30
New COVID Variant Is Emerging; Testing and Vaccine Euphoria May Be Back; Keep Your Watchlist Ready
A new COVID variant, JN.1, is spreading rapidly and has been classified as a "variant of interest" by WHO. If it becomes deadlier, vaccine and...
Tina Banerjee
Follow
805 Views
Share
bullish
•
Taisho Pharmaceutical Holdin
•
03 Dec 2023 14:00
Taisho Pharmaceutical (4581 JP): Japan Catalyst Pushes for a Bump
While justifiable, a bump is unlikely due to the lack of a substantial activist shareholder, irrevocables, no competing bid and the offer’s 55.5%...
Arun George
Follow
492 Views
Share
bullish
•
Taisho Pharmaceutical Holdin
•
24 Nov 2023 16:37
Taisho Pharmaceutical (4581 JP): MBO Tender Offer at JPY8,620
The minimum acceptance condition requires a 44% minority acceptance rate. The offer is attractive vs. historical and peer multiples.
Arun George
Follow
739 Views
Share
First
Previous
1
2
3
4
5
6
7
Next
Last
For Institutional Investors and Financial Services
For Corporate IR and Strategy
For Private Wealth Intermediaries
Pricing
Who We Are
Careers
FAQs
Research Provider Solutions
Syndicate your Publications
Compliance
Terms of Use
Privacy Policy
Press Kit
RSS Feeds
Request a Free Trial
Avail a Transition Account
Guest Posts on Smartkarma
Other Enquiries
Join TL;DR Community
Free Weekly Newsletters
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.44.3
x